A Pilot Study for Managing Depressive Symptoms in Autosomal Dominant Polycystic Kidney Disease (ADPKD)

NCT07745920 | Recruiting

• 1 other identifier: 25-006463
• Study Type: interventional
• Target: 105
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this research is to evaluate the feasibility and effectiveness of Digital Neurotherapy (DNT) or Capacity Coaching (CC) for managing symptoms of depression and self reported pain in Autosomal Dominant Polycystic Kidney Disease (ADPKD) compared to education alone.

Conditions

Autosomal Dominant Polycystic Kidney Disease

Outcome Measures

Primary Outcomes (1)

• Actual use of intervention

  Actual use of each intervention will be reported as the percentage of eligible subjects participating in the assigned interventions at least twice a week for at least 20 minutes per session.

  12 weeks

Secondary Outcomes (1)

• Change in the Montgomery-Asberg Depression Rating Scale (MADRS-S) score

  Baseline, 12 weeks

Study Arms (3)

Mayo Clinic-Approved Education

ACTIVE COMPARATOR

The control group will receive standard of care, Mayo Clinic approved education for a duration of 60 minutes, every 2 weeks for 6 sessions (12 weeks)

Behavioral: Mayo Clinic-Approved Education

Digital Neuropathy

EXPERIMENTAL

The Digital Neuropathy group will utilize the web-based system (REJUVENATE) for a duration of 20 minutes, 4 times per week (12 weeks)

Behavioral: Digital Neuropathy

Capacity Coaching

EXPERIMENTAL

The Capacity Coaching group will participate in calls with a board certified health and wellness coach for a duration of 60 minutes, every 2 weeks, for 6 sessions (12 weeks)

Behavioral: Capacity Coaching

Interventions

Mayo Clinic-Approved Education BEHAVIORAL

Education attention control will be administered by board certified health and wellness coaches via virtual coaching sessions.

Mayo Clinic-Approved Education

Digital Neuropathy BEHAVIORAL

The web-based system (REJUVENATE) consists of a set of cognitive exercises continuously and automatically adjusted in difficulty based on each user's performance to maintain the balance of challenge and success optimal to promote neuroplastic enhancement of target neural systems.

Also known as: REJUVENATE

Digital Neuropathy

Capacity Coaching BEHAVIORAL

Board certified health and wellness coaches will create a plan with subjects to use capacity, defined as patients' abilities and resources, to do self-management work.

Capacity Coaching

Eligibility Criteria

• Age: 18 Years - 70 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Confirmed clinical diagnosis of ADPKD using Pei-Ravine criteria
• Pre-End Stage Kidney Disease, with Stage 1-5 CKD (eGFR \>10 ml/min/1.73m2, with no anticipated dialysis or transplant within 12 months)
• Clinical or self-diagnosis of depression
• English-language fluency

You may not qualify if:

• Suicidal ideation/unstable mental illness of any kind
• Lack of access/ability to use internet-based programs
• eGFR \<10 ml/min/1.73m2
• Anticipated dialysis or transplant within 6 months
• Prior chronic dialysis
• Prior organ (liver or kidney) transplant
• Lack of English language fluency
• Significant cognitive impairment (Mini Mental Status Exam (MMSE))

Sponsors & Collaborators

• Mayo Clinic: lead

Study Sites (1)

Mayo Clinic

Rochester, Minnesota, 55905, United States

RECRUITING

MeSH Terms

Conditions

Polycystic Kidney, Autosomal Dominant

Condition Hierarchy (Ancestors)

Polycystic Kidney Diseases; Kidney Diseases, Cystic; Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Abnormalities, Multiple; Congenital Abnormalities; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Ciliopathies; Genetic Diseases, Inborn

Study Officials

• Neera Dahl, MD, PhD

  Mayo Clinic

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Ryan Helland, CCRP

CONTACT

507-422-3998; RSTTEMPORESGROUP@mayo.edu

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: July 30, 2026
• First Posted: August 4, 2026
• Study Start: June 12, 2026
• Primary Completion (Estimated): July 12, 2027
• Study Completion (Estimated): July 12, 2027
• Last Updated: August 4, 2026

Record last verified: 2026-07

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)